
Exelixis (EXEL) Stock Forecast & Price Target
Exelixis (EXEL) Analyst Ratings
Bulls say
Exelixis Inc. is experiencing robust momentum with its leading product, Cabometyx, particularly in the first-line renal cell carcinoma (RCC) market, where it has achieved a 46% market share, reflecting a year-over-year growth of 15% in total prescription volume. The company is also expanding its gastrointestinal sales team to capitalize on the growing demand for Cabometyx and to prepare for the launch of zanzalintinib in colorectal cancer (CRC), which has shown promising results in the Phase 3 STELLAR-303 trial. Furthermore, Exelixis is set to benefit from a strong balance sheet and sustainable profitability, with revised sales estimates for Cabometyx indicating a positive growth trajectory through fiscal years 2026 to 2028.
Bears say
Exelixis Inc's recent financial performance indicates challenges, particularly with a gross-to-net (GTN) decrease from 30.2% to 28.5% in 4Q25, negatively influenced by lower PHS/340B volumes. Additionally, Cabometyx sales reached $545 million in 4Q25, falling short of consensus estimates which anticipated higher revenues, thereby raising concerns about future growth in a competitive market for renal and hepatocellular carcinoma treatments. The company faces various risks, including commercial pressures on Cabometyx, potential lack of positive clinical trial data, and the threat of generic competition, which collectively contribute to a diminished outlook for the stock.
This aggregate rating is based on analysts' research of Exelixis and is not a guaranteed prediction by Public.com or investment advice.
Exelixis (EXEL) Analyst Forecast & Price Prediction
Start investing in Exelixis (EXEL)
Order type
Buy in
Order amount
Est. shares
0 shares